Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 3Brain Neoplasms 3Uterine Cervical Neoplasms 1Thyroid Neoplasms 1Supratentorial Neoplasms 1Stomach Neoplasms 1Seizures 1Prostatic Neoplasms 1Ovarian Neoplasms 1Ovarian Cysts 1Myofibroma 1Liver Neoplasms 1Hematologic Diseases 1Endobronchial Metastases 1Ear Neoplasms 1Cholecystitis 1Breast Neoplasms 1

Interventions

Brentuximab Vedotin 17fludarabine 9Cyclophosphamide 9dacetuzumab 6Lenalidomide 6Bortezomib 6ruxolitinib 5fludarabine phosphate 5Rituximab 5Melphalan 5Dexamethasone 4Busulfan 4lintuzumab 3Whole-Body Irradiation 3Mycophenolic Acid 3Imatinib Mesylate 3Granulocyte Colony-Stimulating Factor 3Doxorubicin 3Calcium Dobesilate 3Azacitidine 3vosaroxin 2spartalizumab 2ponatinib 2nilotinib 2Vincristine 2Thiotepa 2Tacrolimus 2Sugars 2Stem Cell Transplantation 2Rifampin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Hematologic Diseases × Remifentanil × Clear all
NCT00213239 2019-12-02

A Dose Finding Study of Remifentanil and Propofol for Lumbar Punctures in Children

The Hospital for Sick Children

Phase 1/2 Completed
64 enrolled 5 charts

Hematologic Diseases, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡